Liaoning Chengda Biotechnology Co Ltd
SSE:688739
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CN |
|
Liaoning Chengda Biotechnology Co Ltd
SSE:688739
|
10.8B CNY |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
407.6B USD |
Loading...
|
|
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
208.4B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
125.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
71.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
39.9B EUR |
Loading...
|
Market Distribution
| Min | -2 148% |
| 30th Percentile | 14.3% |
| Median | 23% |
| 70th Percentile | 34.6% |
| Max | 775.2% |
Other Profitability Ratios
Liaoning Chengda Biotechnology Co Ltd
Glance View
Liaoning Chengda Biotechnology Co., Ltd. is engaged in the research, development, manufacture and sale of vaccines. The company is headquartered in Shenyang, Liaoning and currently employs 1,663 full-time employees. The company went IPO on 2021-10-28. The firm's main products include rabies vaccine for human use, freeze-dried rabies vaccine for human use, inactivated Japanese encephalitis vaccine for human use and freeze-dried encephalitis inactivated vaccine. The firm's products include two brands: Chengda Suda and Chengda Libao.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Liaoning Chengda Biotechnology Co Ltd is 79.8%, which is below its 3-year median of 81.6%.
Over the last 3 years, Liaoning Chengda Biotechnology Co Ltd’s Gross Margin has decreased from 88.6% to 79.8%. During this period, it reached a low of 79.8% on Jun 30, 2025 and a high of 88.6% on Jun 30, 2022.
